Pinpoint drug delivery system using hollow bio-nanoparticles

Tadanori Yamada; Masaharu Seno; Akihiko Kondo; Masakazu Ueda; Katsuyuki Tanizawa; Shun'ichi Kuroda

doi:10.1295/koron.61.606

Pinpoint drug delivery system using hollow bio-nanoparticles

Tadanori Yamada, Masaharu Seno, Akihiko Kondo, Masakazu Ueda, Katsuyuki Tanizawa, Shun'ichi Kuroda

Research output: Contribution to journal › Article › peer-review

Abstract

Hepatitis B virus envelope L proteins produced in yeast cells form hollow nanoparticles (L particles, average diameter 220 nm) displaying human liver-specific receptor. Recently, the L particles were found to incorporate genes, proteins, and drugs, and act as an efficient pinpoint delivery system to human liver-derived tissues in xenograft models. By substituting the epidermal growth factor (EGF) for human liver-specific receptor, the mutated L particles showed the affinity to the EGF receptor, not to human liver. Other similar HBV envelope proteins, e.g., M and S particles, have already been commercialized for hepatitis B vaccine, strongly suggesting the safety of L particles in human. These results indicate that the hollow bio-nanoparticles are a promising candidate for the next-generation platform of DDS, especially that related to gene therapy.

Original language	English
Pages (from-to)	606-612
Number of pages	7
Journal	KOBUNSHI RONBUNSHU
Volume	61
Issue number	12
DOIs	https://doi.org/10.1295/koron.61.606
Publication status	Published - Dec 2004

Keywords

Drug delivery system
Gene therapy
Hemophilia
Hepatitis B virus
In vivo
Nanoparticle
Retargeting
Yeast

ASJC Scopus subject areas

Chemical Engineering (miscellaneous)
Materials Science (miscellaneous)
Environmental Science(all)
Polymers and Plastics

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1295/koron.61.606

Cite this

@article{597d6ad65f0d4ea098c79974c3558a0c,

title = "Pinpoint drug delivery system using hollow bio-nanoparticles",

abstract = "Hepatitis B virus envelope L proteins produced in yeast cells form hollow nanoparticles (L particles, average diameter 220 nm) displaying human liver-specific receptor. Recently, the L particles were found to incorporate genes, proteins, and drugs, and act as an efficient pinpoint delivery system to human liver-derived tissues in xenograft models. By substituting the epidermal growth factor (EGF) for human liver-specific receptor, the mutated L particles showed the affinity to the EGF receptor, not to human liver. Other similar HBV envelope proteins, e.g., M and S particles, have already been commercialized for hepatitis B vaccine, strongly suggesting the safety of L particles in human. These results indicate that the hollow bio-nanoparticles are a promising candidate for the next-generation platform of DDS, especially that related to gene therapy.",

keywords = "Drug delivery system, Gene therapy, Hemophilia, Hepatitis B virus, In vivo, Nanoparticle, Retargeting, Yeast",

author = "Tadanori Yamada and Masaharu Seno and Akihiko Kondo and Masakazu Ueda and Katsuyuki Tanizawa and Shun'ichi Kuroda",

year = "2004",

month = dec,

doi = "10.1295/koron.61.606",

language = "English",

volume = "61",

pages = "606--612",

journal = "Kobunshi Ronbunshu",

issn = "0386-2186",

publisher = "Society of Polymer Science",

number = "12",

}

TY - JOUR

T1 - Pinpoint drug delivery system using hollow bio-nanoparticles

AU - Yamada, Tadanori

AU - Seno, Masaharu

AU - Kondo, Akihiko

AU - Ueda, Masakazu

AU - Tanizawa, Katsuyuki

AU - Kuroda, Shun'ichi

PY - 2004/12

Y1 - 2004/12

N2 - Hepatitis B virus envelope L proteins produced in yeast cells form hollow nanoparticles (L particles, average diameter 220 nm) displaying human liver-specific receptor. Recently, the L particles were found to incorporate genes, proteins, and drugs, and act as an efficient pinpoint delivery system to human liver-derived tissues in xenograft models. By substituting the epidermal growth factor (EGF) for human liver-specific receptor, the mutated L particles showed the affinity to the EGF receptor, not to human liver. Other similar HBV envelope proteins, e.g., M and S particles, have already been commercialized for hepatitis B vaccine, strongly suggesting the safety of L particles in human. These results indicate that the hollow bio-nanoparticles are a promising candidate for the next-generation platform of DDS, especially that related to gene therapy.

AB - Hepatitis B virus envelope L proteins produced in yeast cells form hollow nanoparticles (L particles, average diameter 220 nm) displaying human liver-specific receptor. Recently, the L particles were found to incorporate genes, proteins, and drugs, and act as an efficient pinpoint delivery system to human liver-derived tissues in xenograft models. By substituting the epidermal growth factor (EGF) for human liver-specific receptor, the mutated L particles showed the affinity to the EGF receptor, not to human liver. Other similar HBV envelope proteins, e.g., M and S particles, have already been commercialized for hepatitis B vaccine, strongly suggesting the safety of L particles in human. These results indicate that the hollow bio-nanoparticles are a promising candidate for the next-generation platform of DDS, especially that related to gene therapy.

KW - Drug delivery system

KW - Gene therapy

KW - Hemophilia

KW - Hepatitis B virus

KW - In vivo

KW - Nanoparticle

KW - Retargeting

KW - Yeast

UR - http://www.scopus.com/inward/record.url?scp=14044259238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14044259238&partnerID=8YFLogxK

U2 - 10.1295/koron.61.606

DO - 10.1295/koron.61.606

M3 - Article

AN - SCOPUS:14044259238

SN - 0386-2186

VL - 61

SP - 606

EP - 612

JO - Kobunshi Ronbunshu

JF - Kobunshi Ronbunshu

IS - 12

ER -

Pinpoint drug delivery system using hollow bio-nanoparticles

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this